Palvella Therapeutics (NASDAQ:PVLA) Posts Earnings Results, Misses Expectations By $0.35 EPS

Palvella Therapeutics (NASDAQ:PVLA) announced its quarterly earnings results on Tuesday. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.35), Zacks reports.

Here are the key takeaways from Palvella Therapeutics’ conference call:

• QTORIN rapamycin’s NDA remains on track for completion in the second half of 2026, with potential FDA approval in the first half of 2027. FDA granted rolling review, supported by the product’s Fast Track and Breakthrough Therapy designations.
• The company highlighted strong phase III SELVA results in microcystic lymphatic malformations, including improvement in 95% of patients at week 24 and a favorable safety profile. Palvella plans to pursue a broad label that includes pediatric patients and is targeting a potential first-line therapy.
• Palvella is expanding its commercial infrastructure ahead of a potential launch, including increasing its planned sales force to approximately 40 representatives, building medical affairs and patient-support teams, and engaging more than 200 of 400 targeted clinics.
• The pipeline continues to advance, with a phase III study in cutaneous venous malformations expected to begin in the fourth quarter of 2026, a phase II angiokeratoma study already underway, and a phase II DSAP study expected to start in the fourth quarter. The company expects additional QTORIN program announcements later this year.
• FDA did not grant Breakthrough Therapy Designation for the cutaneous venous malformation program based on the initial 12-week data package. Palvella plans to resubmit using 24-week efficacy results and qualitative patient data, while increased commercial and medical investments raised expected 2026 cash expenses to approximately $85 million-$95 million.

Palvella Therapeutics Trading Up 8.0%

NASDAQ:PVLA opened at $151.99 on Wednesday. Palvella Therapeutics has a 12 month low of $36.93 and a 12 month high of $161.38. The company has a market cap of $2.18 billion, a PE ratio of -36.45 and a beta of -0.17. The company has a 50 day simple moving average of $131.42 and a two-hundred day simple moving average of $119.00.

Wall Street Analyst Weigh In

PVLA has been the subject of a number of research analyst reports. Stephens reissued an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a report on Thursday, May 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Chardan Capital raised Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. HC Wainwright reiterated a “buy” rating and issued a $270.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Finally, Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $207.36.

Insiders Place Their Bets

In other news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total transaction of $476,360.46. Following the transaction, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at $238,512.42. This represents a 66.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company’s stock.

Institutional Trading of Palvella Therapeutics

Several large investors have recently modified their holdings of the company. Raymond James Financial Inc. lifted its holdings in Palvella Therapeutics by 476,660.0% in the third quarter. Raymond James Financial Inc. now owns 23,838 shares of the company’s stock valued at $1,494,000 after acquiring an additional 23,833 shares during the period. Mariner LLC bought a new stake in shares of Palvella Therapeutics during the 3rd quarter valued at about $1,299,000. Verition Fund Management LLC bought a new stake in shares of Palvella Therapeutics during the 4th quarter valued at about $1,249,000. Marshall Wace LLP increased its position in shares of Palvella Therapeutics by 61.7% during the 2nd quarter. Marshall Wace LLP now owns 49,077 shares of the company’s stock valued at $1,106,000 after purchasing an additional 18,732 shares during the last quarter. Finally, Alps Advisors Inc. increased its position in shares of Palvella Therapeutics by 77.1% during the 4th quarter. Alps Advisors Inc. now owns 9,716 shares of the company’s stock valued at $1,017,000 after purchasing an additional 4,230 shares during the last quarter. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.